Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study

Long-term survival after lung transplantation is limited due to chronic lung allograft dysfunction (CLAD), which encompasses two main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for (sub)clinical allograft injury and could be a tool for monitoring of lung allograft health across the (pre)clinical spectrum of CLAD. In this proof-of-concept study, we therefore assessed post-transplant plasma dd-cfDNA levels in 20 CLAD patients (11 BOS and 9 RAS) at three consecutive time points free from concurrent infection or acute rejection, during stable condition, preclinical CLAD, and established CLAD (<i>n</i> = 3 × 20 samples). Elevated dd-cfDNA levels were detected in 47% of stable samples, in 66% of preclinical CLAD samples, and in 71% of CLAD samples, indicating ongoing allograft injury. However, dd-cfDNA levels exhibited high intra- and interpatient variability and did not significantly differ between BOS and RAS (<i>p</i> = 0.25), although the range of dd-cfDNA was higher in RAS. Dd-cfDNA detects ongoing allograft injury in patients with CLAD, which warrants further investigation to improve early detection of CLAD.